The Vaccines and Related Biological Products Advisory Committee (VRBPAC) held two sequential votes. The first asked whether mFLUSIVA’s benefits outweigh its risks for adults aged 50 to 64; the panel answered yes, 9–0. The second posed the identical benefit-risk question for adults 65 and older; the panel again voted 9–0 in favor. VRBPAC votes are advisory only — the FDA is not bound by the committee’s recommendations and will issue its own final determination.

The agency’s target action date under the Prescription Drug User Fee Act (PDUFA) is August 5, 2026. The BLA in question is STN 125869/0.

Moderna is seeking two distinct regulatory approvals under a single filing. For adults 50 to 64, the company pursues traditional, standard approval grounded in clinical efficacy data from the pivotal Phase 3 P304 trial, published in the New England Journal of Medicine. That trial, which enrolled more than 40,000 participants across 11 countries, showed mFLUSIVA reduced RT-PCR–confirmed influenza-like illness by 26.6 percent relative to a standard-dose seasonal comparator; when measured against higher-acuity healthcare outcomes — emergency department visits, hospitalizations, and urgent care — relative vaccine efficacy rose to 47.9 percent.

For adults 65 and older, Moderna seeks accelerated approval, a distinct regulatory pathway that permits licensure on the basis of an immunological surrogate endpoint reasonably likely to predict clinical benefit. Accelerated approval carries a statutory obligation: Moderna must complete a confirmatory Phase IV post-market study — expected to enroll up to 800,000 participants across two flu seasons — to verify and describe the clinical benefit in that age group.

The road to the June 18 hearing was unusually turbulent. On February 3, 2026, CBER Director Vinay Prasad issued a rare refusal-to-file letter, declining to initiate review of the original BLA. Prasad’s stated rationale: Moderna’s pivotal trial used a standard-dose comparator for the 65-and-older cohort rather than the high-dose or adjuvanted vaccines that CDC preferentially recommends for older adults, and therefore the study did not qualify as “adequate and well-controlled.” Moderna pushed back publicly, noting that CBER had accepted the standard-dose comparator in writing roughly 18 months earlier. Within days of the refusal — following public criticism and a formal Type A meeting — the FDA reversed course and agreed to file a revised application. Prasad subsequently left the CBER director role in April 2026.

If the FDA follows VRBPAC’s recommendation and approves the BLA by the August 5 PDUFA date, mFLUSIVA would become the first mRNA vaccine licensed for a routinely recurring, annually updated disease in the United States. Moderna already holds approval for an mRNA COVID-19 vaccine, Spikevax; mFLUSIVA would extend that mRNA platform to influenza. The company has said it is prepared to distribute the vaccine in time for the 2026–2027 flu season.

The policy, announced under Commissioner Dr. Marty Makary’s banner of “radical transparency,” ends an arrangement that had held for decades. Previously, a complete response letter (CRL) was confidential unless the sponsor chose to disclose it. Under the new regime, the FDA releases each letter simultaneously with sponsor notification, redacted only for trade secrets, confidential commercial information, and personal data—but with company names intact.

To mark the shift, the agency published a batch of 89 previously unpublished CRLs covering applications that were pending, withdrawn, or abandoned. A searchable database now lives at open.fda.gov, where letters associated with both approved and unapproved applications are indexed in a new transparency endpoint.

Cytisinicline: a live example

The policy’s real-world weight arrived almost immediately. On June 22, 2026, Achieve Life Sciences announced it had received a CRL for its New Drug Application for cytisinicline, a plant-derived partial nicotinic-receptor agonist under review as a smoking-cessation treatment. The letter, publicly released the same day under the new rules, cited outstanding manufacturing observations from a cGMP inspection of a third-party manufacturing facility and incomplete final product labeling—not clinical efficacy or safety concerns. The FDA raised no deficiencies regarding cytisinicline’s clinical data.

Cytisinicline holds Breakthrough Therapy designation (for nicotine e-cigarette/vaping dependence). Achieve Life Sciences said it intends to resubmit the NDA in the fourth quarter of 2026, naming Adare Pharma Solutions as its new primary commercial manufacturing partner, with a potential U.S. approval target in the first half of 2027.

A legal challenge takes shape

Not everyone accepts the policy as lawful. On April 21, 2026, the FDA received a citizen petition filed by Covington & Burling on behalf of an unnamed pharmaceutical company. The petition argues that real-time CRL disclosure may violate federal law—including FOIA, the Trade Secrets Act, and FDA’s own regulations—and that sponsors are denied notice and an opportunity to respond before their letters become public. The petitioners asked the agency to establish a process giving sponsors at least 10 days to contest a planned disclosure before it is made.

Separately, an attorney at Arnold & Porter has argued publicly that the releases of CRLs for unapproved drugs may also conflict with the Administrative Procedure Act.

As of publication, the FDA has not formally responded to the citizen petition, and no litigation has been filed. The policy remains in effect, and every NDA and BLA sponsor now faces the prospect that a rejection letter—whenever it comes—will be a matter of public record the same day it lands in their inbox.

A Split Approval Pathway

The committee’s favorable recommendation covers two distinct regulatory tracks. For adults aged 50 to 64, Moderna is seeking traditional approval on the basis of clinical efficacy data from the P304 pivotal trial published in the New England Journal of Medicine. For adults 65 and older, the company is pursuing accelerated approval, supported by immunogenicity data rather than direct clinical-efficacy measurements — a distinction that will shape product labeling and the post-market commitments required of Moderna if the 65+ indication is granted.

The P304 trial enrolled adults 50 and older and compared mFLUSIVA against a standard-dose licensed quadrivalent influenza vaccine (Fluarix or equivalent) — not a high-dose or recombinant product. Relative vaccine effectiveness against PCR-confirmed influenza-like illness was 26.6% overall, with higher point estimates against A/H1N1 (47.9%) and A/H3N2 (29.6%) strains than against B lineages (22.2%). Against symptomatic influenza illness across all strains, rVE was 29.1%. A separate immunogenicity analysis compared mFLUSIVA to Fluzone High-Dose in adults 65 and older, providing the immunobridging data underpinning the accelerated approval pathway for that cohort.

The comparator matters. The 26.6% rVE reflects improvement over a standard-dose seasonal influenza vaccine, not over a high-dose or recombinant product. VRBPAC panelists noted they would have preferred head-to-head clinical efficacy data against a high-dose comparator for the 65+ population; the immunogenicity bridge was accepted as a surrogate for accelerated approval but leaves clinical efficacy against the strongest available alternatives unconfirmed.

Background: RTF and Resolution

The FDA had previously issued a refuse-to-file letter for the mFLUSIVA application, citing deficiencies in the submission. Moderna subsequently filed additional analyses that addressed those concerns; the agency accepted the resubmission and scheduled the VRBPAC review. The June 18 meeting was the first time panelists formally evaluated the complete data package in a public forum.

Panelists raised questions about the immunobridging approach used to support the accelerated-approval pathway in the 65+ cohort, and noted that head-to-head efficacy data against the high-dose comparator using a clinical (rather than immunogenicity) endpoint would strengthen confidence in that age group.

What Comes Next

The FDA is not obligated to follow advisory committee recommendations, but it does so in the large majority of cases. The PDUFA target date of August 5, 2026, falls immediately before peak vaccination season for Northern Hemisphere influenza, creating a narrow window for label finalization, manufacturing scale-up, and distribution if the product is approved. Moderna has not disclosed a commercial launch timeline or pricing.

Moderna Inc. P304 Phase 3 trial (mRNA-1010): N Engl J Med. 2026; doi:10.1056/NEJMoa2516491. VRBPAC meeting June 18, 2026. PDUFA action date August 5, 2026.

Correction (June 21, 2026): An earlier version of this article stated the P304 trial compared mFLUSIVA against “a high-dose recombinant quadrivalent influenza vaccine.” The P304 efficacy trial used a standard-dose licensed quadrivalent influenza vaccine (Fluarix or equivalent) as its comparator; the 26.6% rVE reflects improvement over a standard-dose baseline. A separate immunogenicity analysis compared mFLUSIVA to Fluzone High-Dose in adults 65 and older, supporting the accelerated approval pathway for that cohort. The front-matter claim, body paragraph, and callout have been corrected.

What the CRL Covers

Cytisinicline is an alkaloid derived from the seeds of Laburnum anagyroides, where it occurs naturally as a partial agonist at α4β2 nicotinic acetylcholine receptors — the same target as varenicline (Chantix/Champix). The compound has been marketed under the name Tabex as an over-the-counter smoking cessation aid in parts of Eastern Europe for decades, but NDA 217082 represents Achieve’s bid for U.S. FDA approval of a rigorously tested, GMP-manufactured formulation.

The FDA’s pre-approval inspection of the drug substance manufacturing facility identified deficiencies in documentation, process validation, or facility standards — the exact nature of which is not disclosed in the public letter. Manufacturing-related CRLs are common in natural-product drug applications, where standardizing extraction yield, batch-to-batch consistency, and impurity profiles to GMP requirements can require facility upgrades that take months to years to complete.

The clinical data package — including the Phase 3 ORCA-2 (810 participants) and ORCA-3 (792 participants) trials, which together demonstrated significant improvement in continuous abstinence rates versus placebo — was not cited as deficient. The science is intact.

Adare and the Manufacturing Path

Achieve has a contract manufacturing agreement with Adare Pharma Solutions, a contract development and manufacturing organization experienced in complex formulations, for cytisinicline drug substance production. The CRL indicates additional remediation will be required. Achieve has stated its intention to respond to the letter and resubmit; no resubmission timeline has been disclosed.

A manufacturing CRL is a setback measured in months to years, not a program-ending event when the clinical evidence is sound. The ORCA trials provide a clear efficacy and tolerability basis; the barrier is logistical, not scientific.

The CNPV Option

Achieve Life Sciences also holds an FDA Commissioner’s National Priority Voucher (CNPV) associated with the cytisinicline program — awarded under the CNPV program established in 2025 for treatments addressing national health priorities, including e-cigarette and vaping cessation. CNPVs, like traditional priority review vouchers, can be transferred to other sponsors who use them to obtain priority review for an unrelated drug application, and provide a potential financing mechanism for remediation and resubmission without a dilutive equity raise. Achieve has not announced its plans for the voucher.

Achieve Life Sciences 8-K, June 2026. Adare Pharma Solutions manufacturing partnership disclosure. Achieve Life Sciences CNPV voucher disclosure, 2026.

Correction (June 21, 2026): An earlier version of this article described Achieve Life Sciences’ voucher as a “non-pediatric rare disease priority review voucher (CNPV).” It is an FDA Commissioner’s National Priority Voucher (CNPV), a separate program established in 2025 for treatments addressing national health priorities such as e-cigarette and vaping cessation. The source title, front-matter claim, and body paragraph have been corrected.

PIVOT-PO Trial: Noninferiority, Not Superiority

Approval rested on the PIVOT-PO trial (NCT06059846), a Phase 3 randomized, controlled noninferiority study in adults with cUTI. Participants were assigned to tebipenem pivoxil 600 mg orally three times daily or imipenem-cilastatin 500 mg intravenously every six hours. The primary endpoint was overall response — a composite of clinical cure and microbiological eradication — at the test-of-cure visit approximately seven days after completing treatment, in the microbiological intent-to-treat (micro-ITT) population.

Overall response was 58.5% with oral tebipenem versus 60.2% with IV imipenem-cilastatin (adjusted difference: −1.3%, 95% CI −7.5% to +4.8%). The result satisfied the pre-specified noninferiority margin of −10 percentage points. The trial was not designed to establish superiority.

Regulatory Context and Prior CRL

The FDA issued a Complete Response Letter for an earlier tebipenem NDA in 2022, following the ADAPT-PO trial, which used ertapenem IV as the comparator. The agency raised adequacy concerns about that trial design. The program was subsequently refiled with PIVOT-PO data using imipenem-cilastatin IV as the comparator — a choice the FDA found sufficient to support approval.

Tebipenem pivoxil carries a QIDP (Qualified Infectious Disease Product) designation under the GAIN Act, granting priority review and a five-year market exclusivity extension. Its significance lies primarily in stewardship: it provides a step-down option for patients who require carbapenem-level coverage for multidrug-resistant Enterobacteriaceae, enabling a transition from intravenous to oral therapy and potentially shortening inpatient stays. The prescribing information includes a boxed warning on Clostridioides difficile–associated diarrhea and specifies use only when oral agents are appropriate and susceptibility testing confirms activity.

PIVOT-PO trial, ClinicalTrials.gov NCT06059846. FDA NDA 216592, June 17, 2026.

Correction — June 20, 2026: An earlier version of this article stated the FDA approved tebipenem pivoxil on June 20, 2026. The FDA acted on June 17, 2026, one day before the PDUFA target date of June 18; the GSK announcement confirming approval was issued the same day. All references have been corrected.

What the Data Showed

The Vaccines and Related Biological Products Advisory Committee (VRBPAC) reviewed pivotal efficacy and safety data from the Phase 3 P304 trial (NCT06602024), which enrolled adults across two influenza seasons. The trial assessed protection against laboratory-confirmed influenza caused by A(H1N1)pdm09, A(H3N2), B/Victoria, and B/Yamagata lineages.

The committee voted on two separate questions, addressing each pathway individually. In both cases, the vote was nine in favor and zero against, with no abstentions.

Different Pathways for Different Age Groups

For adults aged 50 to 64, the committee considered traditional approval, supported by vaccine efficacy data meeting pre-specified primary endpoints. For adults 65 and older, the committee considered accelerated approval, supported by immunogenicity bridging data using hemagglutination inhibition (HAI) titers as a surrogate endpoint. Under accelerated approval, Moderna would be required to conduct a confirmatory trial demonstrating clinical benefit in the ≥65 cohort.

The dual-pathway structure reflects the challenges of running classical efficacy trials in older adults, where immunosenescence limits both absolute efficacy and trial feasibility. Accelerated approval provides a regulatory mechanism to expand access while confirmatory evidence matures.

MFLUSIVA uses the same lipid nanoparticle mRNA delivery platform as Moderna’s COVID-19 vaccine. Safety data across two pivotal seasons showed reactogenicity consistent with the known profile of mRNA vaccines.

Regulatory Context

FDA is not bound by advisory committee recommendations but follows them in the large majority of cases. The PDUFA target action date for MFLUSIVA is August 5, 2026. If licensed, MFLUSIVA would be the first mRNA-based influenza vaccine approved in the United States, extending the platform beyond COVID-19 into a disease that causes an estimated 12,000 to 52,000 deaths annually in the U.S.

VRBPAC meeting, June 18, 2026. P304 trial: ClinicalTrials.gov NCT06602024. PDUFA: August 5, 2026.

What FDA agreed to — and what it did not

The Type B meeting outcome is a pre-submission agreement on the regulatory pathway, not an approval decision. Under Accelerated Approval, FDA may grant conditional marketing authorization based on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit, with a requirement to conduct a confirmatory trial verifying that benefit. The June 2026 agreement means FDA has concluded that the Phase I/II dataset is sufficient to anchor a BLA submission, not that the agency has evaluated or will approve that BLA.

The distinction matters. The news release announcing the outcome uses language about “plan for BLA submission” — not an approval, not an advisory committee date, not a PDUFA date. Those steps remain ahead.

A regulatory about-face — twice

What makes this outcome notable is its position as the second reversal in seven months on the same core question: what kind of Phase 3 confirmatory study FDA would require if AMT-130 receives accelerated approval.

In November 2025, an October 29, 2025 pre-BLA meeting concluded that FDA no longer agreed the existing Phase I/II data were sufficient for a BLA, and that a confirmatory trial with sham surgery would be required — a design that would require some patients with Huntington’s disease to undergo a simulated cranial procedure without receiving the gene therapy. The formal details of the sham-surgery requirement came from a Type A meeting held January 30, 2026, whose minutes were publicly released on March 2, 2026. Both positions generated substantial controversy among HD patient advocates and neurology researchers who argued that sham surgery in this population posed serious ethical and practical barriers to enrollment.

By June 2026, FDA reversed course. The Type B meeting outcome confirms that the confirmatory trial may use a standard-of-care comparator in place of a sham-surgery control — a design change that meaningfully lowers the barrier to conducting that study.

The drug and the designations

AMT-130 is a gene therapy delivered via a single stereotactic intracranial injection. It uses an adeno-associated virus serotype 5 (AAV5) vector to deliver a microRNA construct (miHTT) that lowers total huntingtin — both mutant and wild-type — mRNA expression in the striatum. It is a total HTT-lowering therapy, not a mutant-selective one; this distinction is a subject of ongoing scientific discussion in the Huntington’s disease field. Huntington’s disease is caused by a CAG repeat expansion in the HTT gene, leading to progressive neurodegeneration and death; there is currently no approved disease-modifying therapy.

FDA has granted AMT-130 four designations: Breakthrough Therapy status (April 2025), Regenerative Medicine Advanced Therapy (RMAT) designation — the first RMAT designation for a Huntington’s disease therapy, granted in 2024 — as well as Fast Track and Orphan Drug designations.

The Phase I/II evidence base

The U.S. trial (NCT04120493) enrolled 43 patients across four cohorts. The initial randomized phase included a low-dose cohort and a high-dose cohort, each randomized against a sham-surgery control arm. Subsequent enrollment added Cohort 3 (an expansion/extension cohort) and Cohort 4 (an open-label high-dose cohort in patients with low striatal volume). The European Phase Ib/2 study (NCT05243017) enrolled an additional 14 patients.

In the 12 high-dose patients who reached 36-month follow-up (of 17 treated in the high-dose cohort), mean change from baseline on the composite Unified Huntington’s Disease Rating Scale (cUHDRS) was −0.38, compared with −1.52 in 940 Enroll-HD matched external controls (P=.003). The company described this as approximately 75% slowing of disease progression relative to the external control group. (Company-reported; Phase I/II data not yet peer-reviewed in full.)

CSF neurofilament light chain (NfL) decreased 8.2% from baseline at 36 months in the high-dose group (company-reported). No new drug-related serious adverse events have been reported since December 2022 (company-reported).

What the BLA pathway does not resolve

Accelerated Approval under this pathway would be conditional. The confirmatory trial — now accepted to use a standard-of-care control — must demonstrate clinical benefit on a validated endpoint to convert any accelerated approval to full approval. The BLA submission itself remains ahead, as does FDA’s filing review, a PDUFA action date assignment, and a possible advisory committee. For a disease with no approved disease-modifying therapy, the pathway agreement is meaningful. But the distance between a Type B meeting outcome and an approval is substantial.

All efficacy and safety figures are company-reported from uniQure’s September 2025 and June 2026 press releases and have not been independently peer-reviewed.

Correction (2026-06-19): Two errors corrected by post-publication fact-check. (1) AMT-130 was described as delivering “a microRNA construct that silences mutant huntingtin protein expression”; the therapy (miHTT) lowers total huntingtin — both mutant and wild-type — mRNA expression. It is a total HTT-lowering therapy, not a mutant-selective one. The NCT04120493 trial title explicitly names it “Total Huntingtin Gene (HTT) Lowering Therapy.” (2) The FDA regulatory timeline was imprecisely stated: the March 2, 2026 press release was not a new FDA communication “reaffirming” a November position but the public release of final minutes from a Type A meeting held January 30, 2026. The article has been updated to reflect the correct procedural sequence.

Baloxavir marboxil is the active moiety of Xofluza, licensed by Genentech/Roche in the United States since 2018 for the treatment of acute uncomplicated influenza in patients 12 years and older (and expanded to high-risk patients in October 2019, based on the CAPSTONE-2 trial). Baloxavir inhibits the cap-dependent endonuclease of the influenza polymerase acidic (PA) subunit — a mechanism distinct from the neuraminidase inhibitors (oseltamivir, zanamivir, peramivir). Single-dose oral administration differentiates it from the twice-daily five-day regimens of neuraminidase inhibitors.

Generic entry and access implications

Generic entry typically results in price decreases of 80–90% for small-molecule drugs within two to three years of competition. Xofluza carries a list price in excess of $150 per single dose in the United States; generic baloxavir is expected to enter at a substantially lower price point, expanding access for patients who either lack prescription drug coverage or face high cost-sharing.

The FDA approval also has implications for antiviral stockpiling. The U.S. Strategic National Stockpile maintains influenza antiviral reserves; generic availability lowers the per-course cost of maintaining baloxavir reserves, which are relevant in the context of pre-pandemic preparedness.

Resistance context

Baloxavir carries a class-labeling note regarding the PA/I38T substitution, which confers reduced susceptibility and has been detected in some treated patients, particularly children, in post-marketing surveillance. The prescribing information for the generic is expected to carry the same warnings and contraindications as the reference product. No labeling changes specific to resistance were announced with this approval.

Correction (2026-06-19): Two errors corrected by post-publication fact-check. (1) The headline and dek used “FDA Clears” — terminology specific to medical devices under the 510(k) pathway — for a pharmaceutical ANDA drug approval; the FDA’s own press release uses “Approves.” The article has been corrected throughout to use “approved/approval.” (2) Baloxavir marboxil was expanded to high-risk patients in October 2019 (CAPSTONE-2 trial), not 2021 as stated; no documented Xofluza supplemental approval milestone occurred in 2021.

What FDA’s briefing documents say

The agency released its briefing documents on June 16, 2026. Reviewers found no major deficiencies in the clinical data package and did not request additional studies as a condition of approval. The briefing notes that MFLUSIVA demonstrated noninferiority to licensed comparator quadrivalent influenza vaccines on hemagglutination inhibition (HAI) titers for all four strains in the pivotal immunogenicity program and met pre-specified seroconversion thresholds across age strata.

The 2026 label under review covers adults 50 years of age and older; Moderna’s pediatric program is ongoing under a separate development plan.

P303 IGNITE: the immunogenicity pivot trial

The primary immunogenicity data came from the P303 IGNITE trial (NCT05827978), a randomized, observer-blind, active-controlled study that compared MFLUSIVA with licensed quadrivalent inactivated influenza vaccine (QIV-HD or standard-dose QIV, by age stratum) in adults. The trial enrolled across multiple seasons and countries, measuring day-29 HAI titers and seroconversion rates as the primary endpoints. Moderna published the pivotal immunogenicity and efficacy data in the New England Journal of Medicine on May 6, 2026 (online-first).

The VRBPAC today will vote on whether MFLUSIVA is safe, whether it is effective, and whether the benefit-risk profile supports approval — three separate roll-call votes under the standard committee format.

CBER jurisdiction

Jurisdiction over influenza vaccines sits with the Center for Biologics Evaluation and Research (CBER), not CDER. As of the June 18, 2026 meeting, Karim Mikhail serves as acting CBER Director; Vinay Prasad, MD, MPH, who had been vocal about surrogate-endpoint reliance in influenza vaccine approvals, departed CBER in April 2026. No public statement from the current acting director on MFLUSIVA specifically was available at press time.

A PDUFA date of August 5, 2026 is set for the agency’s final action.

Platform implications

The mRNA platform’s key structural advantage in influenza is speed: while conventional egg-based or cell-based vaccine manufacturing requires 6–9 months to produce a strain-matched seasonal lot, mRNA vaccines can — in principle — compress that to 2–3 months. Regulators and public health officials have long sought that speed advantage for a scenario in which the circulating strain drifts substantially from the vaccine strain in a given season, or in which a novel influenza pandemic strain requires rapid mass production.

Fluzone HD (Sanofi), Flublok (Pfizer), and several adjuvanted formulations currently dominate the high-dose adult market. A positive VRBPAC recommendation does not guarantee FDA approval, but no mRNA BLA has been rejected after a favorable advisory committee vote.

Correction — June 18, 2026: An earlier version of this article identified Vinay Prasad as CBER Director; Prasad departed CBER in April 2026 and Karim Mikhail serves as acting CBER Director as of the date of this meeting. The article also described the MFLUSIVA BLA as covering adults 18 years and older; the BLA under VRBPAC review covers adults 50 years of age and older. The NEJM source DOI has been corrected from NEJMoa2600000 to NEJMoa2516491. These errors were identified by The Vital Record’s post-publication fact-check.

The FDA released briefing documents on June 16, 2026, ahead of a scheduled Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting set for June 18, in which an independent expert panel will assess whether the benefits of MFLUSIVA (mRNA-1010) outweigh its risks for adults 50 years of age and older. The committee’s vote is advisory and nonbinding; it does not constitute approval.

The vaccine, developed by Moderna TX Inc. under Biologics License Application STN 125869/0, would be the first mRNA-based seasonal influenza vaccine to receive FDA approval in the United States if the agency ultimately clears it. The agency’s PDUFA action date — the deadline by which FDA has committed to completing its review — is August 5, 2026.

A turbulent path to the panel

In early February 2026, FDA’s Center for Biologics Evaluation and Research Director Vinay Prasad signed a refusal-to-file letter, declining to review Moderna’s initial submission on the grounds that the comparator used in the company’s Phase 3 trial did not reflect the best-available standard of care in the United States at the time of the study.

Days later, the agency reversed course after Moderna proposed a revised regulatory pathway: full traditional approval for adults aged 50 to 64 years, where efficacy data against a standard-dose comparator were considered sufficient, and accelerated approval for adults 65 and older based on immunogenicity data against a high-dose comparator. Under accelerated approval, Moderna would be required to conduct a post-marketing confirmatory study to secure full approval for the older cohort.

What the briefing documents say

The June 16 briefing documents reflect FDA staff’s findings under that revised framework. Agency scientists concluded that MFLUSIVA met prespecified sequential efficacy and immunogenicity criteria and identified no major safety signals or imbalances in adverse events or deaths between treatment and comparator groups.

FDA staff nonetheless identified several evidence gaps that VRBPAC panelists are expected to probe. Efficacy data derive from a single influenza season, leaving open questions about performance across seasons with differing circulating strains. The briefing also flagged an absence of co-administration data — no trials have evaluated MFLUSIVA given alongside COVID-19, respiratory syncytial virus, or pneumococcal vaccines, all commonly administered to older adults during the same clinical visits. Immunocompromised individuals and frail older adults were not well-represented in the pivotal studies.

Tomorrow, VRBPAC panelists are expected to vote separately on the benefit-risk profile of MFLUSIVA in each age group: adults 50 through 64, and adults 65 and older. A favorable committee vote would be a positive signal, but FDA is not bound by the panel’s recommendation and has until August 5 to render a final decision.

A positive briefing document is not approval. An advisory committee vote in favor is not approval. Only the agency’s written action by the PDUFA date constitutes a regulatory determination.

What FDA agreed to — and what it did not

The Type B meeting outcome is a pre-submission agreement on the regulatory pathway, not an approval decision. Under Accelerated Approval, FDA may grant conditional marketing authorization based on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit, with a requirement to conduct a confirmatory trial verifying that benefit. The June 2026 agreement means FDA has concluded that the Phase I/II dataset is sufficient to anchor a BLA submission, not that the agency has evaluated or will approve that BLA.

The distinction matters. The news release announcing the outcome uses language about “plan for BLA submission” — not an approval, not an advisory committee date, not a PDUFA date. Those steps remain ahead.

A regulatory about-face — twice

What makes this outcome notable is its position as the second reversal in seven months on the same core question: what kind of Phase 3 confirmatory study FDA would require if AMT-130 receives accelerated approval.

In November 2025, FDA informed uniQure that any confirmatory trial must include a sham-surgery control arm — a design requiring that some patients with Huntington’s disease undergo a simulated cranial procedure without receiving the gene therapy. The agency reaffirmed that demand in March 2026. Both positions generated substantial controversy among HD patient advocates and neurology researchers who argued that sham surgery in this population posed serious ethical and practical barriers to enrollment.

By June 2026, FDA reversed course. The Type B meeting outcome confirms that the confirmatory trial may use a standard-of-care comparator in place of a sham-surgery control — a design change that meaningfully lowers the barrier to conducting that study.

The regulatory flip from the November 2025 and March 2026 positions to the June 2026 position represents a substantial shift in FDA’s requirements for this program.

The drug and the designations

AMT-130 is a gene therapy delivered via a single stereotactic intracranial injection. It uses an adeno-associated virus serotype 5 (AAV5) vector to deliver a microRNA construct that silences mutant huntingtin protein expression in the striatum. Huntington’s disease is caused by a CAG repeat expansion in the HTT gene, leading to progressive neurodegeneration and death; there is currently no approved disease-modifying therapy.

FDA has granted AMT-130 four designations: Breakthrough Therapy status (April 2025), Regenerative Medicine Advanced Therapy (RMAT) designation — the first RMAT designation for a Huntington’s disease therapy, granted in 2024 — as well as Fast Track and Orphan Drug designations.

The Phase I/II evidence base

The U.S. trial (NCT04120493) enrolled 43 patients across four cohorts. The initial randomized phase included a low-dose cohort and a high-dose cohort, each randomized against a sham-surgery control arm. Subsequent enrollment added Cohort 3 (an expansion/extension cohort) and Cohort 4 (an open-label high-dose cohort in patients with low striatal volume). The European Phase Ib/2 study (NCT05243017) enrolled an additional 14 patients.

The efficacy and safety data supporting the BLA pathway were reported by uniQure in a September 24, 2025 press release and have not yet been independently peer-reviewed in full. At a September 2025 data cutoff, the company reported the following company-reported figures (Phase I/II data; not peer-reviewed):

In the 12 high-dose patients who reached 36-month follow-up (of 17 treated in the high-dose cohort), mean change from baseline on the composite Unified Huntington’s Disease Rating Scale (cUHDRS) was −0.38, compared with −1.52 in 940 Enroll-HD matched external controls (P=.003). The company described this as representing approximately 75% slowing of disease progression relative to the external control group. (Company-reported; Phase I/II data not yet peer-reviewed in full.)

The cUHDRS comparison uses an external, non-randomized control — the 940 Enroll-HD matched controls are a registry-derived comparator, not patients who were concurrently randomized to a placebo or sham procedure. The 12 patients at 36 months are a subset of the 17 treated in the high-dose cohort; the remaining high-dose patients had not yet reached the 36-month follow-up window at the September 2025 data cutoff.

CSF neurofilament light chain (NfL), a biomarker of neuroaxonal injury used as a secondary measure, decreased 8.2% from baseline at 36 months in the high-dose group (company-reported; not peer-reviewed). No new drug-related serious adverse events have been reported since December 2022 (company-reported).

What the BLA pathway does not resolve

Accelerated Approval under this pathway would be conditional. The confirmatory trial — now accepted to use a standard-of-care control — must demonstrate clinical benefit on a validated endpoint to convert any accelerated approval to full approval. The design, enrollment, and timeline for that confirmatory study have not been publicly specified as of this writing.

The BLA submission itself remains ahead. After filing, FDA will conduct a filing review before accepting the application, assign a PDUFA action date, and may convene an advisory committee. None of those steps has occurred.

For a disease that has had no approved disease-modifying therapy, the pathway agreement is a meaningful development. But the distance between a Type B meeting outcome and an approval is substantial, and each intervening step carries its own review standard.

All efficacy and safety figures from uniQure’s September 2025 and June 2026 press releases are company-reported and have not been independently peer-reviewed. This article will be updated if peer-reviewed data or a formal BLA acceptance are announced.

The affected infants ranged in age from 2 to 5 months when illness began. All three were hospitalized and received BabyBIG® (botulism immune globulin intravenous [human]), the only FDA-approved treatment for infant botulism. No deaths have been reported.

On June 13, 2026, Nara Organics voluntarily recalled all lots of Nara Organics Whole Milk Organic Infant Formula sold through Target stores, Target.com, and Nara.com between July 2025 and June 2026. The recall class has not been confirmed in available public sources; this story will be updated as that information becomes available.

Importantly, no Nara Organics formula has tested positive for Clostridium botulinum as of publication. State officials have collected leftover formula samples for testing; results are expected in the coming weeks. The contamination pathway has not been determined.

Infant botulism — distinct from foodborne botulism — occurs when infants ingest C. botulinum spores that germinate and produce toxin within the intestinal tract. It is not caused by ingesting preformed toxin. The bacteria are widespread in the environment and are occasionally found in dust and soil. Powdered infant formula is not a sterile product.

Federal agencies have not disclosed which botulinum toxin type was confirmed in these cases. Nara Organics accounts for a small fraction of U.S. infant formula sales; widespread shortages from this recall are not expected.

The FDA and CDC are continuing their joint investigation. Caregivers who have used Nara Organics formula and notice symptoms of weakness, poor feeding, weak cry, or constipation in their infant should seek immediate medical attention.

This story will be updated as the investigation progresses.

The recalled products are ChloraPrep Clear Single Sterile 1 mL applicators (Lot 4032183) and FREPP Clear 1.5 mL applicators with paper lidding (Lot 4073005). Both products contain chlorhexidine gluconate and are used to prepare the skin prior to surgery, catheter placement, and other invasive procedures — settings where microbial sterility is critical.

BD identified the contaminating organism as Aspergillus penicillioides, a mold that proliferates under certain environmental conditions. The FDA warns that contamination of a skin-preparation product with this fungus may lead to serious systemic infection, sepsis, and death. The risk is particularly acute for immunocompromised patients — including those undergoing chemotherapy, organ transplant recipients, and people with HIV — for whom invasive aspergillosis carries high mortality.

Both lots were distributed nationwide to hospitals and distributors between March 2024 and June 2024 — approximately 24 to 27 months before the recall announcement. No adverse events had been reported to BD at the time of the recall announcement, according to the FDA notice.

Healthcare facilities should immediately quarantine and discontinue use of any remaining stock from these lots and contact their BD representative to arrange return and replacement of affected units.

Note: The FDA recall classification for this action could not be confirmed directly from the FDA page at time of filing — editors should verify the classification field against the live FDA record at the URL cited above.

The action is a full approval, not an accelerated pathway decision — a distinction that matters given the prior ODAC vote (7-1 in favor) and the trial’s enrollment scope.

The approval rests on the Phase III CAPItello-281 trial (NCT04493853), which enrolled 1,012 adults with PTEN-deficient tumors confirmed by IHC. Patients were randomized 1:1 to intermittent capivasertib 400 mg twice daily (4 days on / 3 days off) plus abiraterone and androgen deprivation therapy, or placebo plus abiraterone and ADT. The primary endpoint — investigator-assessed radiographic progression-free survival — was met: median rPFS was 33.2 months in the capivasertib arm versus 25.7 months in the placebo arm (HR 0.81; 95% CI 0.66–0.98; P = .034), a 7.5-month absolute improvement. Results were published in the Annals of Oncology (PMID 41120017).

Interim overall survival data, at 26.4% event maturity, showed an HR of 0.90 (95% CI 0.71–1.15; P = .401) — a non-significant and immature result that remains a key secondary endpoint under continued follow-up.

The safety profile reflected on-target AKT pathway toxicity: diarrhea was reported in approximately 52% of patients in the capivasertib arm, hyperglycemia in approximately 38%, and rash in approximately 35%.

The Roche VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC test run on the BenchMark ULTRA automated staining platform. It is the first assay FDA-approved as a companion diagnostic to assess PTEN protein — as opposed to PTEN gene deletion by FISH or sequencing — in prostate cancer tissue. Approximately 25% of patients with mHSPC carry PTEN-deficient tumors; in the CAPItello-281 screened population, 1,519 of 6,003 patients with valid tumor results (25.3%) were PTEN-deficient by IHC.

Capivasertib’s first FDA approval was in November 2023 for HR-positive, HER2-negative advanced breast cancer in combination with fulvestrant, based on CAPItello-291. The prostate cancer approval is the drug’s second indication.

Sources: AstraZeneca press release June 12, 2026; Roche press release June 12, 2026; Annals of Oncology PMID 41120017.

Who it is — and is not — for

The expanded clearance is limited to children who do not use insulin. This includes children with type 2 diabetes or prediabetes managed with oral medications, and children and caregivers who want to understand how food, exercise, and lifestyle factors affect glucose levels.

Stelo is not indicated for people who use insulin, including children with type 1 diabetes or any form of insulin-dependent diabetes. Parents should not purchase this device as a replacement for a prescription CGM for a child whose diabetes requires insulin or careful clinical glucose management. Consult a pediatrician or pediatric endocrinologist about the right monitoring approach for a child with diagnosed diabetes.

Key device features and limitations

The Stelo biosensor is a wearable sensor worn on the back of the upper arm for up to 15 days, transmitting glucose readings to a companion smartphone app every 15 minutes. An optional caregiver-device viewing feature allows parents to monitor readings remotely.

An important limitation: Stelo does not include a hypoglycemia alert. The system is not designed to notify users when blood glucose drops to dangerously low levels. This is a critical limitation for any child with conditions that cause problematic or unpredictable low blood sugar.

The FDA’s clearance relied on real-world evidence from adult and pediatric iCGM users in lieu of a dedicated pediatric trial — a regulatory approach the agency has used to extend evidence-based device clearances to new populations.

Dexcom received initial OTC clearance for Stelo for adults 18 and older in March 2024. The June 2026 pediatric expansion follows a review of real-world performance data.

The EUA covers tablets manufactured by Felix Pharmaceuticals Pvt Ltd (Ireland), which are already sold over the counter for flea treatment. The authorization adds a new indication: treatment of Cochliomyia hominivorax (New World screwworm) larval infestation in companion animals.

Who it covers

The authorization applies to dogs and cats — including puppies and kittens — that weigh at least two pounds and are at least four weeks old. It does not cover horses, livestock, or other species.

Treatment, not prevention

This is a treatment authorization only. Nitenpyram is authorized to treat confirmed or suspected NWS infestations — not to prevent them. Pet owners in or near affected areas should not administer nitenpyram prophylactically.

Veterinary care is essential

Although nitenpyram is available OTC, screwworm myiasis is a serious wound-based parasitic condition that requires more than oral medication. Pet owners who notice signs of infestation should contact a veterinarian immediately. Nitenpyram treats the infestation systemically, but the wound itself requires cleaning, debridement, and follow-up care that only a veterinarian can appropriately provide.

Outbreak context

As of the EUA’s issuance, seven confirmed NWS cases had been reported in the United States: six in Texas and one in a dog from New Mexico. The nitenpyram EUA is the 10th EUA FDA has issued for animal drugs to combat the current NWS threat, alongside three conditional approvals.

The approval is based on LITESPARK-022 (NCT05239728), a randomised, double-blind, placebo-controlled Phase 3 trial in which patients who had undergone nephrectomy for high-risk ccRCC were randomised to belzutifan plus pembrolizumab or placebo plus pembrolizumab. The primary endpoint was disease-free survival. The combination produced a statistically significant DFS improvement: hazard ratio 0.72 (95% CI 0.59–0.87), a 28% reduction in the risk of recurrence or death compared with pembrolizumab plus placebo.

Belzutifan, a selective oral HIF-2α inhibitor, was first approved in 2021 for adults with von Hippel-Lindau disease-associated tumours. In clear-cell RCC, loss of the VHL tumour suppressor gene leads to constitutive HIF-2α activity, driving expression of VEGF, erythropoietin, and other factors that fuel tumour growth and immune evasion. By inhibiting HIF-2α directly, belzutifan targets the disease’s primary transcriptional driver rather than its downstream effectors.

Pembrolizumab, a PD-1 checkpoint inhibitor, received its own adjuvant RCC approval in August 2022 based on KEYNOTE-564 (DFS HR 0.68). Adding belzutifan to that established backbone appears to confer additional recurrence reduction, though no head-to-head trial versus adjuvant pembrolizumab monotherapy has been conducted and absolute benefit magnitude will require longer follow-up and patient-level analysis.

High-risk criteria in LITESPARK-022 included pT2 disease with Grade 4 or sarcomatoid differentiation; pT3a or higher; regional lymph node involvement (pN+); or M1 disease rendered no evidence of disease by prior complete resection. Common adverse events included anaemia and fatigue, consistent with prior belzutifan experience, plus immune-mediated events at rates expected for pembrolizumab.

The approval extends the therapeutic arc of belzutifan, which also holds approval in the metastatic ccRCC setting in combination with lenvatinib (LITESPARK-023). Merck’s HIF-2α programme now spans the full treatment continuum — adjuvant, first-line metastatic, and subsequent lines — a breadth not previously achieved with a single targeted agent in kidney cancer.

Cytisinicline is a plant-derived partial agonist of the α4β2 nicotinic acetylcholine receptor subtype, the same molecular target as varenicline. It is extracted from the common laburnum tree (Cytisus laburnum) and has been used as a smoking cessation treatment in Eastern Europe since the 1960s under the brand name Tabex — an unusually long real-world record for a drug now seeking Western regulatory approval — but without the double-blind, placebo-controlled evidence package the FDA requires.

Achieve Life Sciences conducted two U.S. Phase 3 trials, ORCA-2 and ORCA-3, both of which met their primary endpoint. In ORCA-3, the continuous abstinence rate at weeks 9–12 was 30.3% for cytisinicline versus 9.4% for placebo — a statistically significant difference consistent in magnitude with the benefit seen with varenicline in that endpoint. The NDA is based on the ORCA programme.

Achieve holds Breakthrough Therapy Designation for cytisinicline in electronic cigarette and vaping cessation — a separate indication from the smoking cessation NDA under review. A Commissioner’s National Priority Voucher attached to the programme similarly references the vaping indication. The June 20 PDUFA concerns the smoking NDA and rests on the ORCA data alone.

Varenicline was withdrawn from the U.S. market in 2021 due to nitrosamine impurity concerns and returned as a reformulated generic in 2022. Cytisinicline has a distinct chemical structure and independent manufacturing profile; the sponsor has provided a nitrosamine impurity assessment as part of its NDA submission.

If approved, cytisinicline would enter a market currently served by nicotine replacement therapy, varenicline, and bupropion. Pricing and reimbursement terms have not been disclosed. The drug is currently available in some European countries without prescription; a U.S. launch would require domestic manufacturing capacity.

What bemotrizinol is — and why it took so long

Bemotrizinol is a broad-spectrum UV filter that absorbs across both the UVA and UVB ranges. It has been in commercial sunscreens in the European Union since 2000 and is widely used across Asia, where it is marketed by Swiss-Dutch manufacturer DSM-Firmenich under the trade name Parsol Shield. The ingredient is notable for its photostability: studies show that more than 98% of the molecule remains intact even after high-dose UV exposure, a contrast to older chemical filters that can degrade in sunlight and may require pairing with stabilizers.

The previous benchmark for U.S. sunscreen chemistry was set in 1999, when the FDA finalized the OTC sunscreen monograph that included avobenzone as the last new chemical UV filter cleared for widespread use. For more than two decades after that, a backlog of applications for newer European and Asian filters — including several submitted in the mid-2000s — stalled under the legacy rulemaking process, which required formal Federal Register rulemaking that could take many years.

The CARES Act pathway

The Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 overhauled the OTC monograph system, replacing the slow rulemaking track with a faster administrative order process. OTC000039 is the first new active ingredient added to any OTC monograph under that streamlined authority — a proof of concept for a pathway lawmakers designed in part to resolve exactly this kind of multi-decade logjam.

FDA issued a proposed order in December 2025, accepted public comment through January 26, 2026, and finalized the order within roughly six months — a pace that would have been difficult under the prior framework.

What the order authorizes

Under OTC000039, manufacturers may include bemotrizinol at concentrations up to 6% in finished sunscreen drug products. The FDA determined the ingredient is generally recognized as safe and effective (GRASE) for use by adults and children 6 months of age and older — consistent with the labeling standard applied to other OTC sunscreen actives.

In its scientific review, the agency found that bemotrizinol is minimally absorbed through the skin into systemic circulation, a characteristic that distinguished it favorably from some older chemical filters currently under closer scrutiny. Studies submitted to FDA showed no evidence of skin irritation, sensitization, photo-allergenic response, or phototoxicity.

Exclusivity and market timeline

DSM-Firmenich, which filed the original petition, holds an 18-month market exclusivity period under the CARES Act framework, running from the date the first commercial product containing BEMT goes on sale in the United States. The company has signaled that consumer products could reach shelves as early as late summer 2026. After the exclusivity window closes, any sunscreen manufacturer may formulate with bemotrizinol under the monograph conditions.

The FDA’s order does not constitute a new drug approval; rather, it is a GRASE determination under the OTC monograph system, which governs how active ingredients may be used in self-care drug products sold without a prescription.

The NDA is supported primarily by data from the Phase 3 lidERA Breast Cancer trial (NCT04961996), a global randomized study that enrolled 4,170 patients with medium- or high-risk early-stage ER+/HER2– breast cancer post-surgery. Patients received either 30 mg giredestrant orally once daily or physician’s choice of standard endocrine monotherapy (an aromatase inhibitor or tamoxifen) for at least five years.

The trial met its primary endpoint of invasive disease-free survival (IDFS). Giredestrant reduced the hazard of invasive disease recurrence or death by 30% relative to standard endocrine therapy (hazard ratio 0.70; 95% CI, 0.57–0.87; p = 0.0014). At three years, IDFS rates were 92.4% in the giredestrant arm versus 89.6% in the control arm — an absolute difference of approximately 2.8 percentage points. The benefit was consistent across both premenopausal (HR 0.65) and postmenopausal (HR 0.74) subgroups. Results were presented at the 2025 San Antonio Breast Cancer Symposium.

SERDs work by binding to the estrogen receptor and triggering its degradation, blocking the hormonal signaling that drives most ER+ tumors. Fulvestrant, the only currently approved SERD, is administered by intramuscular injection. Giredestrant would be the first oral SERD with positive Phase 3 data in the curative-intent (adjuvant) setting, a distinction Roche has highlighted in its regulatory filings.

If approved, giredestrant would compete with aromatase inhibitors — the current standard of care for adjuvant endocrine therapy — which are also orally administered. The key differentiation from AIs is the degrader mechanism; whether that translates to durable clinical benefit over a five-to-ten-year adjuvant course will be a central question for FDA reviewers.

Giredestrant is investigational and has not been approved by the FDA for any use. This article describes a regulatory filing, not an approved therapy.

The committee will discuss and make recommendations on Biologics License Application STN 125869/0. VRBPAC’s vote is advisory, not decisive; the agency retains full authority over the final licensing decision. FDA has set a PDUFA goal date of August 5, 2026.

What the panel will weigh

Moderna is pursuing a split-pathway strategy. For adults aged 50 to 64, the company is seeking standard full approval, supported by efficacy data from the pivotal Phase 3 P304 trial. For adults 65 and older — a population at highest risk from influenza complications — Moderna is requesting accelerated approval, supported by immunogenicity bridging from the P303 Part C study.

Phase 3 efficacy snapshot

The P304 trial, published May 6, 2026 in the New England Journal of Medicine (394:1803–1813; DOI: 10.1056/NEJMoa2516491), randomized 40,805 adults aged 50 and older across 11 countries. mRNA-1010 achieved a relative vaccine efficacy of 26.6% (95% CI: 16.7%–35.4%) against PCR-confirmed influenza illness compared with a licensed standard-dose comparator, meeting the protocol’s prespecified superiority criterion. Strain-specific estimates: rVE 29.6% for A/H1N1, 22.2% for A/H3N2, and 29.1% for B/Victoria lineages. In participants 65 and older, rVE was 27.4%. The safety profile was consistent with prior studies; no significant safety concerns were identified.

A rocky regulatory path

On February 3, 2026, FDA’s Center for Biologics Evaluation and Research issued a Refuse-to-File letter citing a single technical concern: the choice of a licensed standard-dose influenza vaccine as the comparator in P304. No safety or efficacy concerns with the vaccine itself were raised.

Following a Type A meeting with regulators, Moderna resubmitted an amended BLA. The agency reversed course, accepted the application, and assigned the August 5 PDUFA date — an unusual outcome that underscored the agency’s view that the underlying data package was scientifically sound.

“Approval would mark a technology milestone: the first mRNA platform vaccine licensed for a pathogen other than SARS-CoV-2.”

Approximately 40,000 to 50,000 Americans die from influenza-associated illness each year. Whether VRBPAC’s recommendation, and any subsequent FDA decision, can move the needle on that burden is the core question hanging over the June 18 session.

Correction, June 10, 2026: The original dek stated “eight months after a Refuse-to-File stumble.” The RTF letter was issued on February 3, 2026; the VRBPAC meeting is June 18, 2026 — an interval of approximately four months, not eight. Corrected to “four months.”

Vedolizumab is an integrin receptor antagonist that binds the α4β7 integrin to blunt the migration of white blood cells into gut tissue. It is approved for adults with moderately to severely active ulcerative colitis and Crohn’s disease. AVT16 is being developed as a lyophilized vial for intravenous infusion.

What acceptance does — and doesn’t — establish

Acceptance starts the FDA’s review clock; it is not approval. Alvotech says the filing rests on “analytical, pharmacokinetic, and immunogenicity data” to support biosimilarity. Notably, the company states that the pivotal clinical study tested a different molecule: a randomized, double-blind, single-dose, parallel-group, three-arm trial of AVT80 — a subcutaneous candidate — against vedolizumab in healthy adults, which “met all its primary endpoints.” On regulatory advice, that trial is being used to support clinical similarity for both AVT16 and AVT80.

“Biosimilarity and interchangeability have not been established by regulatory authorities and are not claimed,” the company’s release states.

Two cautions for readers. The press release reports no participant counts, no pharmacokinetic confidence intervals, and no target action date, so those numbers cannot be printed here. And the interchangeability designation — which would permit pharmacy-level substitution without prescriber sign-off — remains a request, not a ruling. In the European Union, the European Medicines Agency has validated a marketing application covering both AVT16 and AVT80.

What the trial actually showed

Approval rested on VERITAC-2 (NCT05654623), a phase 3, open-label, randomized trial reported in The New England Journal of Medicine. It enrolled 624 patients who had received one prior line of a CDK4/6 inhibitor plus endocrine therapy, and up to one additional line of endocrine therapy; they were randomized 1:1 to vepdegestrant 200 mg orally once daily or fulvestrant 500 mg intramuscularly. The primary endpoint was progression-free survival (PFS) by blinded independent central review, tested in both the ESR1-mutated subgroup and the full population.

Among the 270 patients with ESR1 mutations, median PFS was 5.0 months (95% CI, 3.7 to 7.4) with vepdegestrant versus 2.1 months (95% CI, 1.9 to 3.5) with fulvestrant — a hazard ratio of 0.58 (95% CI, 0.43 to 0.78; P<0.001).

In the full randomized population, the benefit did not hold: median PFS was 3.8 versus 3.6 months (HR 0.83; 95% CI, 0.69 to 1.01; P=0.07).

That split — a clear win in the biomarker-defined subgroup, a miss overall — is precisely why the label is restricted to ESR1-mutated disease and why the companion diagnostic matters. ESR1 mutations are an acquired resistance mechanism to prior endocrine therapy, and they are the setting where a degrader’s mechanism is most plausibly advantaged. (The FDA’s own review reported a marginally different subgroup figure for the same data — HR 0.57; 95% CI, 0.42 to 0.77; P=0.0001 — versus the NEJM publication’s HR of 0.58. The figures cited above follow the peer-reviewed NEJM report; the small discrepancy reflects the FDA regulatory dataset.)

Safety: not a benign drug

In the trial, 23.4% of vepdegestrant-treated patients had a grade 3 or higher adverse event versus 17.6% of fulvestrant-treated patients; adverse events led to discontinuation in 2.9% of the vepdegestrant arm versus 0.7% of the fulvestrant arm. Most events were low grade. Per the prescribing information, the most common adverse reactions (≥10%) included fatigue, musculoskeletal pain, nausea, decreased appetite, and laboratory abnormalities — elevated AST and ALT, anemia (decreased hemoglobin), and neutropenia (decreased neutrophils) — so the harms picture is broader than the single grade 3-or-higher aggregate.

Two label warnings are clinically material. First, QTc interval prolongation: the prescribing information warns that vepdegestrant can prolong the QT (QTc) interval, which can lead to life-threatening arrhythmia, and advises serial ECG monitoring — an ECG before starting treatment and again roughly four weeks after initiation, with correction of hypokalemia and hypomagnesemia before and during treatment; the label directs clinicians not to start the drug in patients with a QTc above 470 msec. Second, embryo-fetal toxicity: based on animal data and its mechanism, vepdegestrant can cause fetal harm and must not be used in pregnancy. Because breast cancer also affects premenopausal women, this matters in practice: the label advises females of reproductive potential to use effective non-hormonal contraception during treatment and for at least 2 weeks after the final dose.

The trial was funded by Pfizer and Arvinas.

The result validates targeted protein degradation as a clinical strategy. It does not yet show a survival advantage, and the effect size in absolute terms — under three months of additional median PFS in the ESR1-mutated subgroup — is modest. Overall survival data were immature at the primary analysis.

DECNUPAZ is not the first CD123-targeted agent for the disease: tagraxofusp-erzs (Elzonris) was approved for BPDCN in 2018 and described by the FDA as the first CD123-targeted therapy. AbbVie’s narrower claim is that DECNUPAZ is “the first and only” CD123-targeting antibody-drug conjugate (the company’s own term for the mechanism) that can be initiated in an outpatient setting — a logistics distinction, not a clinical-benefit one.

The approval covers both newly diagnosed and relapsed or refractory BPDCN, and rests on the single-arm CADENZA study (NCT03386513), an AbbVie-sponsored Phase 1/2 open-label trial. Per ClinicalTrials.gov, the pre-specified primary endpoint was composite complete response rate (CR plus clinical CR) — a response-rate surrogate. Duration of response, the share of patients bridged to stem-cell transplant, and overall survival were secondary endpoints. There was no comparator arm.

What the data showed

Among 33 newly diagnosed patients, the composite complete response rate was 69.7% (95% CI 51.3-84.4), with a median duration of response of 9.7 months (95% CI 2.9 months to not estimable — the data are immature, and the upper bound has not been reached); 39.4% (13/33) went on to a post-treatment stem-cell transplant. Among 51 relapsed or refractory patients, the composite complete response rate was 15.7% (95% CI 7.0-28.6), with a median duration of response of 9.2 months; 11.8% (6/51) proceeded to transplant. The single best number, 69.7%, applies only to the newly diagnosed subgroup and should not be read as the drug’s overall efficacy.

Composite complete response is a response-rate surrogate. With no control arm, the trial has not demonstrated an overall-survival benefit, and the durability estimate remains immature.

The label carries a boxed warning for hepatotoxicity, including hepatic veno-occlusive disease (also known as sinusoidal obstruction syndrome); per the FDA-approved prescribing information, DECNUPAZ “can cause hepatotoxicity, including severe or fatal hepatic VOD.” The trial protocol excluded patients with a prior history of veno-occlusive disease and with Grade 4 capillary leak syndrome, underscoring the toxicity profile of CD123-targeted agents.

DECNUPAZ is given intravenously on a 21-day cycle (0.045 mg/kg once every three weeks). AbbVie says it can be initiated in an outpatient setting.

Salanersen (also known as BIIB115) uses the same basic strategy as Biogen’s approved drug nusinersen (Spinraza): an antisense oligonucleotide delivered into the spinal fluid, designed to correct splicing of the SMN2 gene’s pre-mRNA and raise production of survival motor neuron (SMN) protein. The pitch for the successor molecule is convenience. Under its FDA label, nusinersen maintenance is dosed once every four months — three lumbar punctures a year. Biogen is targeting one dose a year for salanersen, though that regimen is a development goal for an in-trial drug, not an approved schedule.

What the early data are — and are not

Biogen attributes its efficacy signals to what it calls a Phase 1b study: an open-label, single-arm cohort of 24 children aged 0.5 to 12 years who had previously received the gene therapy onasemnogene abeparvovec (Zolgensma) and had a suboptimal response. In its June 4 release, the company reports that 12 of the 24 achieved at least one new World Health Organization (WHO) motor milestone, that all 24 showed increases from baseline on one or more endpoints, and that neurofilament light chain (NfL) fell 75% at six months.

Three caveats are essential. First, those numbers are company-reported and described by Biogen itself as an exploratory analysis; they have not appeared in a peer-reviewed paper. Second, the cohort is open-label, single-arm and uncontrolled — with no comparator, the milestone and motor-function changes cannot be separated from natural history or from the prior gene therapy. Third, NfL is a surrogate biomarker of nerve-cell damage, not a measure of clinical benefit; a fall in NfL is not the same as a proven improvement in survival or function.

Biogen reports that 12 of 24 children gained a new motor milestone and that NfL fell 75% at six months — but these are exploratory, uncontrolled, company-stated figures, not peer-reviewed efficacy and not a clinical-benefit endpoint.

The registered early-phase study on ClinicalTrials.gov, NCT05575011, is broader than that pediatric read-out. It is a Phase 1 trial with planned enrollment of 62, combining a randomized, placebo-controlled single-ascending-dose arm in healthy adult male volunteers (Part A) with an open-label, multiple-ascending-dose arm plus long-term extension in post-gene-therapy pediatric SMA participants (Part B). Its registered primary endpoint is safety — adverse events and serious adverse events — with pharmacokinetics in cerebrospinal fluid and serum as the secondary measures. No results have been posted to the registry, and the study is not finished: its registered primary completion date is in November 2031, reflecting that long-term extension. Biogen has not stated on the registry how its “Phase 1b” n=24 figures map onto this study’s Part B.

The pivotal program is only now starting

The confirmatory evidence is years away. The registry lists three Phase 3 trials. STELLAR-1 (NCT07221669) is an open-label study in presymptomatic infants, now recruiting, with co-primary efficacy endpoints: the share of infants with two SMN2 copies sitting unsupported at 12 months, and of those with three copies walking alone at 18 months. SOLAR (NCT07444476) is an open-label study in people aged 15 to 60 who are treatment-naive or previously on risdiplam, also recruiting, with a primary endpoint of change from baseline on the Hammersmith Functional Motor Scale–Expanded at 12 months in the treatment-naive cohort. STELLAR-2 (NCT07444450) is a randomized, double-blind, sham-controlled study in infants after gene therapy, not yet recruiting, whose registered primary endpoint is safety. Registered primary completion dates run from June 2028 (SOLAR) and November 2028 (STELLAR-1) into July 2029 (STELLAR-2).

Until those read-outs, the case for salanersen is a dosing-burden argument supported by early, exploratory, uncontrolled data — not a confirmed efficacy win.

The recommendation rests on SERENA-6, a phase III, double-blind, randomised trial that tested a novel idea: act on resistance before a scan shows it. ESR1 mutations are the most common acquired-resistance mechanism to aromatase-inhibitor-based therapy, and they surface in circulating tumour DNA (ctDNA) before radiologic progression.

A molecular trigger, not a radiologic one

Investigators screened 3,256 patients with ctDNA testing every two to three months. The 315 who had a detectable ESR1 mutation without radiologic progression were randomised 1:1 to switch to camizestrant while continuing the same CDK4/6 inhibitor (157 patients), or to stay on their aromatase inhibitor plus CDK4/6 inhibitor (158 patients).

On the primary endpoint, investigator-assessed progression-free survival, median PFS was 16.0 months (95% CI, 12.7 to 18.2) with camizestrant versus 9.2 months (95% CI, 7.2 to 9.5) with the continued aromatase inhibitor — a hazard ratio for progression or death of 0.44 (95% CI, 0.31 to 0.60; P<0.0001) at a median follow-up of 12.6 months.

Median progression-free survival reached 16.0 months with camizestrant versus 9.2 months on the continued aromatase inhibitor.

A secondary patient-reported endpoint also favoured the switch: median time to deterioration in global health status and quality of life was 21.0 months versus 6.4 months (hazard ratio, 0.54; 95% CI, 0.34 to 0.84). Few patients stopped treatment because of adverse events: 1.3% of camizestrant-treated patients and 1.9% of aromatase-inhibitor-treated patients discontinued for that reason.

One caveat carries weight. SERENA-6 read out at an interim analysis, and overall survival was immature. Independent commentators have noted that it remains unproven whether switching at molecular progression improves long-term outcomes versus switching at conventional clinical progression. A CHMP positive opinion is a recommendation; a European Commission decision on the marketing authorisation follows.

The draft outlines how sponsors of human gene therapy products that use genome editing in human somatic cells can lean on “existing scientific and regulatory knowledge” — publicly available information and established platform knowledge spanning chemistry, manufacturing and controls (CMC), nonclinical results and clinical data — to streamline submissions. The stated aim is to reduce “redundant testing” for patients with rare and life-threatening diseases.

Efficiency, not a lowered bar

CBER officials were careful to frame the move as procedural, not a relaxation of standards. “Leveraging prior knowledge does not mean lowering the bar; it means raising our collective efficiency while maintaining the highest standards of safety and efficacy,” said Vijay Kumar, acting director of CBER’s Office of Therapeutic Products. Acting CBER director Karim Mikhail tied the action to getting therapies to patients “faster.”

“In all cases, sponsors should provide a scientific rationale demonstrating the applicability of the data being leveraged.”

That caveat is the load-bearing one: reuse must be justified product by product. The guidance complements the agency’s Plausible Mechanism Framework and its recent draft on assessing off-target editing via next-generation sequencing. The FDA is also steering sponsors toward early engagement — INTERACT and pre-IND meetings — before an IND is filed.

This is a draft, not a binding rule. Comments are due within 90 days of Federal Register publication, after which the FDA says it will review them before finalizing.

The clearance rests on SCORPIO-PEP, a Phase 3 randomized, double-blind, placebo-controlled trial sponsored by Shionogi and registered as NCT05897541. Unlike many approvals announced ahead of publication, the full dataset was already in the public record: the results appeared in the New England Journal of Medicine on May 14, 2026, weeks before the FDA decision.

What the trial reported

In the modified intention-to-treat population — the 2,041 household contacts who tested negative for SARS-CoV-2 at baseline and received at least one dose (ensitrelvir n=1,030, placebo n=1,011) — the incidence of COVID-19 by day 10 was 2.9% on ensitrelvir versus 9.0% on placebo (risk ratio 0.33; 95% CI 0.22 to 0.49; P<0.001), according to the NEJM paper. That was the prespecified primary endpoint, defined as a central-laboratory-confirmed positive RT-PCR plus at least one of 14 prespecified COVID-19 symptoms lasting at least 48 hours.

The 67% figure Shionogi leads with is the relative risk reduction (1 minus the 0.33 risk ratio). In absolute terms, the difference is about 6.1 percentage points — roughly 16 household contacts treated to prevent one case of symptomatic COVID-19 over the 10-day window.

The headline is a 67% relative reduction. The underlying numbers — 2.9% versus 9.0%, a number-needed-to-treat near 16 — are now public in NEJM, so readers can size the benefit for themselves.

The dosing regimen runs five days: a 375 mg loading dose on day one, followed by 125 mg on days two through five. On safety, the NEJM authors reported adverse events in 15.1% of the ensitrelvir group and 15.5% of placebo (serious adverse events 0.2% in each group), with no COVID-19-related hospitalizations or deaths in either arm. Those rates come from the larger safety population (ensitrelvir n=1,190, placebo n=1,187), not the modified intention-to-treat efficacy population.

How it is meant to be used — and who was not studied

This is a prescription-only, post-exposure regimen, not something to self-initiate or stockpile. In the trial, a contact could receive ensitrelvir only after a confirmed symptomatic index case in the household and a baseline-negative SARS-CoV-2 test in the contact, with randomization within 72 hours of symptom onset in the index case. Both gates — a documented infected index case and a negative test in the person being treated — are built into the regimen as studied; the dosing schedule above should not be read as a course anyone can start on their own.

Ensitrelvir is also a strong CYP3A inhibitor and carries clinically important drug-drug interactions, so real-world use requires a clinician to screen a contact’s full medication list before prescribing. SCORPIO-PEP itself excluded anyone who had used a strong CYP3A inducer or a St. John’s wort product within 14 days before enrollment, underscoring that interaction screening is part of safe use rather than an afterthought.

Several populations relevant to safe use were excluded from the pivotal trial, so the NEJM efficacy and safety data do not speak to them. SCORPIO-PEP excluded people with severe renal impairment (creatinine clearance below 30 mL/min or requiring dialysis), those with severe hepatic dysfunction such as cirrhosis or hepatic decompensation, and pregnant or lactating individuals. Clinicians weighing the drug for any of these groups are extrapolating beyond the trial population.

Two further caveats are worth flagging. The trial enrolled from June 2023 through September 2024, a window dominated by then-circulating variants; durability against newer lineages is not addressed by these data. And the ClinicalTrials.gov registry still shows no posted results table (has_results: false), so the registry-level summary lags the peer-reviewed publication. The NEJM paper, not the registry, is the primary source for the efficacy and safety figures here.

When finalized, it would let sponsors draw on publicly available information and established platform knowledge — including chemistry, manufacturing and controls (CMC) data, nonclinical study results and clinical information — to streamline submissions for products that use genome editing in human somatic cells. The agency frames the payoff for patients with rare and life-threatening diseases who have few or no other treatment options, where editing platforms are often reused across indications.

Efficiency, not a lower bar

“Leveraging prior knowledge does not mean lowering the bar; it means raising our collective efficiency while maintaining the highest standards of safety and efficacy.” — Vijay Kumar, M.D., Acting Director, Office of Therapeutic Products, CBER

Karim Mikhail, Acting Director of the Center for Biologics Evaluation and Research, said the approach is meant to build “on what is already known” to accelerate innovation “without compromising the rigorous scientific standards that patients and the public depend on.”

This is a draft, not binding policy, and reflects the FDA’s current thinking only. It complements the agency’s Plausible Mechanism Framework and a companion draft on safety assessment of off-target editing using next-generation sequencing. Comments are due within 90 days of Federal Register publication. How far reviewers will let one product’s data stand in for another’s is a question the review division will settle case by case — not the guidance text.

The approval targets a stubborn clinical problem: patients whose hypertension persists on two, three, or more agents. Aldosterone dysregulation is a recognized driver of that resistance, and baxdrostat works by inhibiting the enzyme that synthesizes the hormone rather than by blocking its receptor.

What the pivotal trial showed

The decision rests on BaxHTN (NCT06034743), a Phase 3, multinational, double-blind, randomized, placebo-controlled trial. After a two-week placebo run-in, 796 patients were randomized 1:1:1 to baxdrostat 1 mg, baxdrostat 2 mg, or placebo on top of background therapy; 794 were treated (264, 266, and 264, respectively). Enrollees had seated systolic pressure of 140 to under 170 mmHg despite stable treatment with two antihypertensives (uncontrolled hypertension) or three or more (resistant hypertension), one of which was a diuretic.

The primary endpoint was the change in seated systolic blood pressure from baseline to week 12. Least-squares mean reductions were 14.5 mmHg (95% CI, -16.5 to -12.5) with 1 mg, 15.7 mmHg (95% CI, -17.6 to -13.7) with 2 mg, and 5.8 mmHg (95% CI, -7.9 to -3.8) with placebo.

The placebo-corrected difference was 8.7 mmHg (95% CI, -11.5 to -5.8) for the 1-mg dose and 9.8 mmHg (95% CI, -12.6 to -7.0) for the 2-mg dose (P<0.001 for both).

On safety, a potassium level above 6.0 mmol/L — a known concern with drugs acting on the aldosterone axis — was reported in 6 patients (2.3%) on 1 mg, 8 patients (3.0%) on 2 mg, and 1 patient (0.4%) on placebo. Importantly, BaxHTN excluded the patients at highest risk of this harm: eligibility required an eGFR of at least 45 mL/min/1.73m2 and a baseline serum potassium below 5.0 mmol/L, so people with significant chronic kidney disease or pre-existing hyperkalemia were not studied. Because aldosterone-axis drugs raise potassium most in patients with reduced kidney function, the observed 2-3% rate of potassium above 6.0 mmol/L may understate hyperkalemia risk in the broader real-world population, where chronic kidney disease is common. Potassium and kidney function require monitoring with this drug class, meaning hyperkalemia is a managed, not negligible, risk rather than an isolated statistic.

BaxHTN measured blood pressure, a surrogate, over 12 weeks; it was not designed to show reductions in heart attacks, strokes, or death, and longer-term cardiovascular and renal outcomes remain to be established. The trial was funded by AstraZeneca and others. The full results were published in the New England Journal of Medicine.

Approval was based on MYR301 (NCT03852719), an open-label Phase 3 trial that randomized 150 patients to bulevirtide 2 mg daily, bulevirtide 10 mg daily, or delayed treatment as the control arm.

What the trial showed

The primary endpoint was combined response at Week 48, defined as undetectable HDV RNA or a decrease of at least 2 log10 IU/mL, plus normalization of ALT. In the 10 mg arm, 48.0% of patients met that endpoint, versus 2.0% on delayed treatment, a difference of 46.0 percentage points (96% CI, 30.5 to 61.4; p<0.0001, Fisher exact). The 2 mg arm reached 44.9%.

Combined virologic and biochemical response is a surrogate; whether bulevirtide changes clinical outcomes such as liver failure or death has not been established.

On secondary endpoints at Week 48, undetectable HDV RNA was reached by 20.0% of the 10 mg arm versus none of the controls, and ALT normalized in 56.0% versus 11.8%.

Because the approval is accelerated and rests on surrogate measures, Gilead must verify clinical benefit in a confirmatory trial. The label carries a boxed warning for post-treatment severe acute exacerbation of hepatitis D and B, with monitoring advised for at least six months after the drug is stopped. HDV, which infects only people already carrying hepatitis B, had no FDA-approved therapy before this clearance.

The recommendation is broad. It covers adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF) — two populations where, in the committee’s words, “there are limited treatment options.” A CHMP positive opinion is not itself a marketing authorisation; the European Commission issues the binding decision, typically within about two months.

What the trial showed

The IPF case rests on FIBRONEER-IPF, a phase 3, double-blind trial that randomly assigned 1,177 patients in a 1:1:1 ratio to nerandomilast 18 mg twice daily, nerandomilast 9 mg twice daily, or placebo; 77.7% were already taking nintedanib or pirfenidone. The primary endpoint was the absolute change from baseline in forced vital capacity (FVC) at week 52.

At 52 weeks, the 18-mg dose slowed FVC decline by 68.8 mL versus placebo (95% CI, 30.3 to 107.4; P<0.001).

The 9-mg arm showed a 44.9 mL difference versus placebo (95% CI, 6.4 to 83.3; P=0.02). Both active arms still lost lung function over the 52 weeks — just less than placebo. Diarrhea was the most common adverse event, reported in 41.3% of the 18-mg group and 31.1% of the 9-mg group, versus 16.0% on placebo.

Nerandomilast (BI 1015550) is described in the trial report as an orally administered preferential inhibitor of phosphodiesterase 4B (PDE4B), with antifibrotic and immunomodulatory effects. The report characterises that mechanism as distinct from nintedanib and pirfenidone, the two antifibrotics that have anchored IPF care since the mid-2010s; that comparison is the publication’s editorial framing and was not stated by the regulator.